Revelation Partners is Lead Investor Backing Rosetta Capital to Purchase Seven Biotech Assets From Schroder UK Public Private Trust plc
Revelation Capital Management, LLC ("Revelation Partners"), a San Francisco-based investment firm focused on the healthcare sector, backed Rosetta Capital VI, LP ("Rosetta") in the acquisition of seven biotech assets from Schroder UK Public Private Trust plc ("SUPP") in an £85.0 million transaction. The closing of the acquisition occurred on March 15, 2021.
Evidation Raises $153M to Scale Virtual Health Capabilities of Achievement™ Platform
Evidation Health today announced the close of $153 million in Series E growth funding to rapidly expand its virtual health programs on AchievementTM, the largest digital health network in the United States. The round was co-led by OMERS Growth Equity and Kaiser Permanente Group Trust; existing investors, including McKesson Ventures and B Capital Group also participated.
Revelation Partners Closes Revelation Healthcare Fund III at Hard Cap of $350MM
Revelation Partners, a dedicated secondary investor in healthcare, announced the first and final closing of its newest fund, Revelation Healthcare Fund III, at its hard cap of $350 million. The oversubscribed offering surpassed the initial target of $300 million and builds on the long-term investment success of the firm.
Syapse Announces $68 Million Strategic Investment with Ally Bridge Group and Northpond Ventures to Expand Delivery of Real-World Evidence Through Syapse’s Learning Health Network
Syapse®, a leading real-world evidence company accelerating the delivery of precision medicine through the Syapse Learning Health NetworkTM, today announced the closing of a $68 million growth equity investment to expand Syapse’s focus on providing real-world insights to partners and assist them in improving outcomes for people with cancer.
SetPoint Medical Raises $64M in Preferred Stock Financing to Support Pivotal Trial for its Novel Bioelectronic Platform
SetPoint Medical Corporation today announced raising $64M in a Preferred Stock Financing to support its RESET-RA pivotal trial in patients with rheumatoid arthritis (RA). The company is developing its platform for the treatment of chronic, inflammation-mediated autoimmune diseases and is initially focused on a potentially efficacious, yet less immunosuppressive option for the treatment of RA.
Boston Scientific buying cardiac health company Preventice Solutions in deal worth up to $1.2B
Boston Scientific Corp. said it has agreed to acquire Preventice Solutions Inc. for $925 million up front and up to an additional $300 million in a potential commercial milestone payment. The former has been an investor in Preventice since 2015 and currently holds an equity stake of about 22%, which is expected...